Kyowa Kirin Presents Positive Mogamulizumab Results from German Study
What happened
Kyowa Kirin announced the final results of the German MINT study, which evaluated mogamulizumab in patients with mycosis fungoides and Sézary Syndrome. The company-sponsored study, conducted across 18 centers, analyzed 109 patients and reported a median time-to-next-treatment of 14.9 months and a 62.4% best overall response rate. The findings were presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group Annual Meeting in Berlin.
From finanznachrichten.de
Why it matters
The results add to the growing body of evidence supporting mogamulizumab's use in routine clinical practice. These findings could influence market access and regulatory considerations for the drug within the European Union.
From finanznachrichten.de
Who's involved
- Kyowa KirinPharmaceutical company that conducted the study and announced the final results.
- BerlinCity where Kyowa Kirin presented the study findings.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Jefferies Financial GroupSpeculative
Positive clinical data might affect Jefferies Financial Group's investment ratings or analysis.
Keep exploring
The entities involved
-
Kyowa Kirin
pharmaceutical company
Nothing else this week.
- Berlin